#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Abnormal fronto-limbic engagement in incarcerated stimulant users during moral processing Rationale Stimulant use is a significant and prevalent problem, particularly in criminal populations.
1-1	0-8	Abnormal	_
1-2	9-22	fronto-limbic	_
1-3	23-33	engagement	_
1-4	34-36	in	_
1-5	37-49	incarcerated	_
1-6	50-59	stimulant	_
1-7	60-65	users	_
1-8	66-72	during	_
1-9	73-78	moral	_
1-10	79-89	processing	_
1-11	90-99	Rationale	_
1-12	100-109	Stimulant	_
1-13	110-113	use	_
1-14	114-116	is	_
1-15	117-118	a	_
1-16	119-130	significant	_
1-17	131-134	and	_
1-18	135-144	prevalent	_
1-19	145-152	problem	_
1-20	153-154	,	_
1-21	155-167	particularly	_
1-22	168-170	in	_
1-23	171-179	criminal	_
1-24	180-191	populations	_
1-25	192-193	.	_

Text=Previous studies found that cocaine and methamphetamine use is related to impairment in identifying emotions and empathy.
2-1	194-202	Previous	_
2-2	203-210	studies	_
2-3	211-216	found	_
2-4	217-221	that	_
2-5	222-229	cocaine	_
2-6	230-233	and	_
2-7	234-249	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
2-8	250-253	use	_
2-9	254-256	is	_
2-10	257-264	related	_
2-11	265-267	to	_
2-12	268-278	impairment	_
2-13	279-281	in	_
2-14	282-293	identifying	_
2-15	294-302	emotions	_
2-16	303-306	and	_
2-17	307-314	empathy	_
2-18	315-316	.	_

Text=Stimulant users also have abnormal neural structure and function of the ventromedial prefrontal cortex (vmPFC), amygdala, anterior (ACC) and posterior cingulate (PCC), regions implicated in moral decision making.
3-1	317-326	Stimulant	_
3-2	327-332	users	_
3-3	333-337	also	_
3-4	338-342	have	_
3-5	343-351	abnormal	_
3-6	352-358	neural	_
3-7	359-368	structure	_
3-8	369-372	and	_
3-9	373-381	function	_
3-10	382-384	of	_
3-11	385-388	the	_
3-12	389-401	ventromedial	_
3-13	402-412	prefrontal	_
3-14	413-419	cortex	_
3-15	420-421	(	_
3-16	422-427	vmPFC	_
3-17	428-429	)	_
3-18	430-431	,	_
3-19	432-440	amygdala	_
3-20	441-442	,	_
3-21	443-451	anterior	_
3-22	452-453	(	_
3-23	454-457	ACC	_
3-24	458-459	)	_
3-25	460-463	and	_
3-26	464-473	posterior	_
3-27	474-483	cingulate	_
3-28	484-485	(	_
3-29	486-489	PCC	_
3-30	490-491	)	_
3-31	492-493	,	_
3-32	494-501	regions	_
3-33	502-512	implicated	_
3-34	513-515	in	_
3-35	516-521	moral	_
3-36	522-530	decision	_
3-37	531-537	making	_
3-38	538-539	.	_

Text=However, no research has studied the neural correlates of stimulant use and explicit moral processing in an incarcerated population.
4-1	540-547	However	_
4-2	548-549	,	_
4-3	550-552	no	_
4-4	553-561	research	_
4-5	562-565	has	_
4-6	566-573	studied	_
4-7	574-577	the	_
4-8	578-584	neural	_
4-9	585-595	correlates	_
4-10	596-598	of	_
4-11	599-608	stimulant	_
4-12	609-612	use	_
4-13	613-616	and	_
4-14	617-625	explicit	_
4-15	626-631	moral	_
4-16	632-642	processing	_
4-17	643-645	in	_
4-18	646-648	an	_
4-19	649-661	incarcerated	_
4-20	662-672	population	_
4-21	673-674	.	_

Text=Objectives Here we examine how stimulant use affects sociomoral processing that might contribute to antisocial behavior.
5-1	675-685	Objectives	_
5-2	686-690	Here	_
5-3	691-693	we	_
5-4	694-701	examine	_
5-5	702-705	how	_
5-6	706-715	stimulant	_
5-7	716-719	use	_
5-8	720-727	affects	_
5-9	728-738	sociomoral	_
5-10	739-749	processing	_
5-11	750-754	that	_
5-12	755-760	might	_
5-13	761-771	contribute	_
5-14	772-774	to	_
5-15	775-785	antisocial	_
5-16	786-794	behavior	_
5-17	795-796	.	_

Text=We predicted that vmPFC, amygdala, PCC, and ACC would show abnormal neural response during a moral processing task in incarcerated methamphetamine and cocaine users.
6-1	797-799	We	_
6-2	800-809	predicted	_
6-3	810-814	that	_
6-4	815-820	vmPFC	_
6-5	821-822	,	_
6-6	823-831	amygdala	_
6-7	832-833	,	_
6-8	834-837	PCC	_
6-9	838-839	,	_
6-10	840-843	and	_
6-11	844-847	ACC	_
6-12	848-853	would	_
6-13	854-858	show	_
6-14	859-867	abnormal	_
6-15	868-874	neural	_
6-16	875-883	response	_
6-17	884-890	during	_
6-18	891-892	a	_
6-19	893-898	moral	_
6-20	899-909	processing	_
6-21	910-914	task	_
6-22	915-917	in	_
6-23	918-930	incarcerated	_
6-24	931-946	methamphetamine	_
6-25	947-950	and	_
6-26	951-958	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
6-27	959-964	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
6-28	965-966	.	_

Text=Methods Incarcerated adult males (N = 211) were scanned with a Mobile MRI system while completing a moral decision making task.
7-1	967-974	Methods	_
7-2	975-987	Incarcerated	_
7-3	988-993	adult	_
7-4	994-999	males	_
7-5	1000-1001	(	_
7-6	1002-1003	N	_
7-7	1004-1005	=	_
7-8	1006-1009	211	_
7-9	1010-1011	)	_
7-10	1012-1016	were	_
7-11	1017-1024	scanned	_
7-12	1025-1029	with	_
7-13	1030-1031	a	_
7-14	1032-1038	Mobile	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
7-15	1039-1042	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
7-16	1043-1049	system	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
7-17	1050-1055	while	_
7-18	1056-1066	completing	_
7-19	1067-1068	a	_
7-20	1069-1074	moral	_
7-21	1075-1083	decision	_
7-22	1084-1090	making	_
7-23	1091-1095	task	_
7-24	1096-1097	.	_

Text=Lifetime drug use was assessed.
8-1	1098-1106	Lifetime	_
8-2	1107-1111	drug	_
8-3	1112-1115	use	_
8-4	1116-1119	was	_
8-5	1120-1128	assessed	_
8-6	1129-1130	.	_

Text=Neural responses during moral processing were compared between users and non-users.
9-1	1131-1137	Neural	_
9-2	1138-1147	responses	_
9-3	1148-1154	during	_
9-4	1155-1160	moral	_
9-5	1161-1171	processing	_
9-6	1172-1176	were	_
9-7	1177-1185	compared	_
9-8	1186-1193	between	_
9-9	1194-1199	users	_
9-10	1200-1203	and	_
9-11	1204-1213	non-users	_
9-12	1214-1215	.	_

Text=The relationship between duration of use and neural function was also examined.
10-1	1216-1219	The	_
10-2	1220-1232	relationship	_
10-3	1233-1240	between	_
10-4	1241-1249	duration	_
10-5	1250-1252	of	_
10-6	1253-1256	use	_
10-7	1257-1260	and	_
10-8	1261-1267	neural	_
10-9	1268-1276	function	_
10-10	1277-1280	was	_
10-11	1281-1285	also	_
10-12	1286-1294	examined	_
10-13	1295-1296	.	_

Text=Results Incarcerated stimulant users showed less amygdala engagement than non-users during moral processing.
11-1	1297-1304	Results	_
11-2	1305-1317	Incarcerated	_
11-3	1318-1327	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
11-4	1328-1333	users	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
11-5	1334-1340	showed	_
11-6	1341-1345	less	_
11-7	1346-1354	amygdala	_
11-8	1355-1365	engagement	_
11-9	1366-1370	than	_
11-10	1371-1380	non-users	_
11-11	1381-1387	during	_
11-12	1388-1393	moral	_
11-13	1394-1404	processing	_
11-14	1405-1406	.	_

Text=Duration of stimulant use was negatively associated with activity in ACC and positively associated with vmPFC response during moral processing.
12-1	1407-1415	Duration	_
12-2	1416-1418	of	_
12-3	1419-1428	stimulant	_
12-4	1429-1432	use	_
12-5	1433-1436	was	_
12-6	1437-1447	negatively	_
12-7	1448-1458	associated	_
12-8	1459-1463	with	_
12-9	1464-1472	activity	_
12-10	1473-1475	in	_
12-11	1476-1479	ACC	_
12-12	1480-1483	and	_
12-13	1484-1494	positively	_
12-14	1495-1505	associated	_
12-15	1506-1510	with	_
12-16	1511-1516	vmPFC	_
12-17	1517-1525	response	_
12-18	1526-1532	during	_
12-19	1533-1538	moral	_
12-20	1539-1549	processing	_
12-21	1550-1551	.	_

Text=Conclusions These results suggest a dynamic pattern of fronto-limbic moral processing related to stimulant use with deficits in both central motive and cognitive integration elements of biological moral processes theory.
13-1	1552-1563	Conclusions	_
13-2	1564-1569	These	_
13-3	1570-1577	results	_
13-4	1578-1585	suggest	_
13-5	1586-1587	a	_
13-6	1588-1595	dynamic	_
13-7	1596-1603	pattern	_
13-8	1604-1606	of	_
13-9	1607-1620	fronto-limbic	_
13-10	1621-1626	moral	_
13-11	1627-1637	processing	_
13-12	1638-1645	related	_
13-13	1646-1648	to	_
13-14	1649-1658	stimulant	_
13-15	1659-1662	use	_
13-16	1663-1667	with	_
13-17	1668-1676	deficits	_
13-18	1677-1679	in	_
13-19	1680-1684	both	_
13-20	1685-1692	central	_
13-21	1693-1699	motive	_
13-22	1700-1703	and	_
13-23	1704-1713	cognitive	_
13-24	1714-1725	integration	_
13-25	1726-1734	elements	_
13-26	1735-1737	of	_
13-27	1738-1748	biological	_
13-28	1749-1754	moral	_
13-29	1755-1764	processes	_
13-30	1765-1771	theory	_
13-31	1772-1773	.	_

Text=This increases our understanding of how drug use relates to moral processing in the brain in an ultra-high risk population.
14-1	1774-1778	This	_
14-2	1779-1788	increases	_
14-3	1789-1792	our	_
14-4	1793-1806	understanding	_
14-5	1807-1809	of	_
14-6	1810-1813	how	_
14-7	1814-1818	drug	_
14-8	1819-1822	use	_
14-9	1823-1830	relates	_
14-10	1831-1833	to	_
14-11	1834-1839	moral	_
14-12	1840-1850	processing	_
14-13	1851-1853	in	_
14-14	1854-1857	the	_
14-15	1858-1863	brain	_
14-16	1864-1866	in	_
14-17	1867-1869	an	_
14-18	1870-1880	ultra-high	_
14-19	1881-1885	risk	_
14-20	1886-1896	population	_
14-21	1897-1898	.	_

Text=Methods Participants Participants were adult males incarcerated in New Mexico and Wisconsin prisons (N= 211).
15-1	1899-1906	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
15-2	1907-1919	Participants	_
15-3	1920-1932	Participants	_
15-4	1933-1937	were	_
15-5	1938-1943	adult	_
15-6	1944-1949	males	_
15-7	1950-1962	incarcerated	_
15-8	1963-1965	in	_
15-9	1966-1969	New	_
15-10	1970-1976	Mexico	_
15-11	1977-1980	and	_
15-12	1981-1990	Wisconsin	_
15-13	1991-1998	prisons	_
15-14	1999-2000	(	_
15-15	2001-2003	N=	_
15-16	2004-2007	211	_
15-17	2008-2009	)	_
15-18	2010-2011	.	_

Text=Inclusion criteria were: age between 18 and 65, IQ of 80 or above, at least 4th grade English reading level, and no history of neurological disorder or history of psychosis in self or first-degree relative.
16-1	2012-2021	Inclusion	_
16-2	2022-2030	criteria	_
16-3	2031-2035	were	_
16-4	2036-2037	:	_
16-5	2038-2041	age	_
16-6	2042-2049	between	_
16-7	2050-2052	18	_
16-8	2053-2056	and	_
16-9	2057-2059	65	_
16-10	2060-2061	,	_
16-11	2062-2064	IQ	_
16-12	2065-2067	of	_
16-13	2068-2070	80	_
16-14	2071-2073	or	_
16-15	2074-2079	above	_
16-16	2080-2081	,	_
16-17	2082-2084	at	_
16-18	2085-2090	least	_
16-19	2091-2094	4th	_
16-20	2095-2100	grade	_
16-21	2101-2108	English	_
16-22	2109-2116	reading	_
16-23	2117-2122	level	_
16-24	2123-2124	,	_
16-25	2125-2128	and	_
16-26	2129-2131	no	_
16-27	2132-2139	history	_
16-28	2140-2142	of	_
16-29	2143-2155	neurological	_
16-30	2156-2164	disorder	_
16-31	2165-2167	or	_
16-32	2168-2175	history	_
16-33	2176-2178	of	_
16-34	2179-2188	psychosis	_
16-35	2189-2191	in	_
16-36	2192-2196	self	_
16-37	2197-2199	or	_
16-38	2200-2212	first-degree	_
16-39	2213-2221	relative	_
16-40	2222-2223	.	_

Text=Participants with a history of regular stimulant use (n = 131) were compared to participants with no history of regular stimulant use (n = 80).
17-1	2224-2236	Participants	_
17-2	2237-2241	with	_
17-3	2242-2243	a	_
17-4	2244-2251	history	_
17-5	2252-2254	of	_
17-6	2255-2262	regular	_
17-7	2263-2272	stimulant	_
17-8	2273-2276	use	_
17-9	2277-2278	(	_
17-10	2279-2280	n	_
17-11	2281-2282	=	_
17-12	2283-2286	131	_
17-13	2287-2288	)	_
17-14	2289-2293	were	_
17-15	2294-2302	compared	_
17-16	2303-2305	to	_
17-17	2306-2318	participants	_
17-18	2319-2323	with	_
17-19	2324-2326	no	_
17-20	2327-2334	history	_
17-21	2335-2337	of	_
17-22	2338-2345	regular	_
17-23	2346-2355	stimulant	_
17-24	2356-2359	use	_
17-25	2360-2361	(	_
17-26	2362-2363	n	_
17-27	2364-2365	=	_
17-28	2366-2368	80	_
17-29	2369-2370	)	_
17-30	2371-2372	.	_

Text=Characteristics of each group are provided in Table 1.
18-1	2373-2388	Characteristics	_
18-2	2389-2391	of	_
18-3	2392-2396	each	_
18-4	2397-2402	group	_
18-5	2403-2406	are	_
18-6	2407-2415	provided	_
18-7	2416-2418	in	_
18-8	2419-2424	Table	_
18-9	2425-2426	1	_
18-10	2427-2428	.	_

Text=All participants provided written, informed consent prior to their inclusion in the study and were compensated at an hourly rate comparable to pay rates for work within the facilities.
19-1	2429-2432	All	_
19-2	2433-2445	participants	_
19-3	2446-2454	provided	_
19-4	2455-2462	written	_
19-5	2463-2464	,	_
19-6	2465-2473	informed	_
19-7	2474-2481	consent	_
19-8	2482-2487	prior	_
19-9	2488-2490	to	_
19-10	2491-2496	their	_
19-11	2497-2506	inclusion	_
19-12	2507-2509	in	_
19-13	2510-2513	the	_
19-14	2514-2519	study	_
19-15	2520-2523	and	_
19-16	2524-2528	were	_
19-17	2529-2540	compensated	_
19-18	2541-2543	at	_
19-19	2544-2546	an	_
19-20	2547-2553	hourly	_
19-21	2554-2558	rate	_
19-22	2559-2569	comparable	_
19-23	2570-2572	to	_
19-24	2573-2576	pay	_
19-25	2577-2582	rates	_
19-26	2583-2586	for	_
19-27	2587-2591	work	_
19-28	2592-2598	within	_
19-29	2599-2602	the	_
19-30	2603-2613	facilities	_
19-31	2614-2615	.	_

Text=All procedures and materials were approved by the University of New Mexico Institutional Review Board (IRB) and thus have been performed in accordance with the ethical standards of the Declaration of Helsinki.
20-1	2616-2619	All	_
20-2	2620-2630	procedures	_
20-3	2631-2634	and	_
20-4	2635-2644	materials	_
20-5	2645-2649	were	_
20-6	2650-2658	approved	_
20-7	2659-2661	by	_
20-8	2662-2665	the	_
20-9	2666-2676	University	_
20-10	2677-2679	of	_
20-11	2680-2683	New	_
20-12	2684-2690	Mexico	_
20-13	2691-2704	Institutional	_
20-14	2705-2711	Review	_
20-15	2712-2717	Board	_
20-16	2718-2719	(	_
20-17	2720-2723	IRB	_
20-18	2724-2725	)	_
20-19	2726-2729	and	_
20-20	2730-2734	thus	_
20-21	2735-2739	have	_
20-22	2740-2744	been	_
20-23	2745-2754	performed	_
20-24	2755-2757	in	_
20-25	2758-2768	accordance	_
20-26	2769-2773	with	_
20-27	2774-2777	the	_
20-28	2778-2785	ethical	_
20-29	2786-2795	standards	_
20-30	2796-2798	of	_
20-31	2799-2802	the	_
20-32	2803-2814	Declaration	_
20-33	2815-2817	of	_
20-34	2818-2826	Helsinki	_
20-35	2827-2828	.	_

Text=Assessments Substance use was assessed using a modified version of the Addiction Severity Index (ASI-X), in which participants were asked about characteristics of use for a variety of substance classes, including age of first use and years of regular use (defined as three or more times a week).
21-1	2829-2840	Assessments	_
21-2	2841-2850	Substance	_
21-3	2851-2854	use	_
21-4	2855-2858	was	_
21-5	2859-2867	assessed	_
21-6	2868-2873	using	_
21-7	2874-2875	a	_
21-8	2876-2884	modified	_
21-9	2885-2892	version	_
21-10	2893-2895	of	_
21-11	2896-2899	the	_
21-12	2900-2909	Addiction	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
21-13	2910-2918	Severity	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
21-14	2919-2924	Index	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
21-15	2925-2926	(	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
21-16	2927-2932	ASI-X	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
21-17	2933-2934	)	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
21-18	2935-2936	,	_
21-19	2937-2939	in	_
21-20	2940-2945	which	_
21-21	2946-2958	participants	_
21-22	2959-2963	were	_
21-23	2964-2969	asked	_
21-24	2970-2975	about	_
21-25	2976-2991	characteristics	_
21-26	2992-2994	of	_
21-27	2995-2998	use	_
21-28	2999-3002	for	_
21-29	3003-3004	a	_
21-30	3005-3012	variety	_
21-31	3013-3015	of	_
21-32	3016-3025	substance	_
21-33	3026-3033	classes	_
21-34	3034-3035	,	_
21-35	3036-3045	including	_
21-36	3046-3049	age	_
21-37	3050-3052	of	_
21-38	3053-3058	first	_
21-39	3059-3062	use	_
21-40	3063-3066	and	_
21-41	3067-3072	years	_
21-42	3073-3075	of	_
21-43	3076-3083	regular	_
21-44	3084-3087	use	_
21-45	3088-3089	(	_
21-46	3090-3097	defined	_
21-47	3098-3100	as	_
21-48	3101-3106	three	_
21-49	3107-3109	or	_
21-50	3110-3114	more	_
21-51	3115-3120	times	_
21-52	3121-3122	a	_
21-53	3123-3127	week	_
21-54	3128-3129	)	_
21-55	3130-3131	.	_

Text=If a participant had any regular use of cocaine or methamphetamine in his lifetime, he was classified as a lifetime stimulant user.
22-1	3132-3134	If	_
22-2	3135-3136	a	_
22-3	3137-3148	participant	_
22-4	3149-3152	had	_
22-5	3153-3156	any	_
22-6	3157-3164	regular	_
22-7	3165-3168	use	_
22-8	3169-3171	of	_
22-9	3172-3179	cocaine	_
22-10	3180-3182	or	_
22-11	3183-3198	methamphetamine	_
22-12	3199-3201	in	_
22-13	3202-3205	his	_
22-14	3206-3214	lifetime	_
22-15	3215-3216	,	_
22-16	3217-3219	he	_
22-17	3220-3223	was	_
22-18	3224-3234	classified	_
22-19	3235-3237	as	_
22-20	3238-3239	a	_
22-21	3240-3248	lifetime	_
22-22	3249-3258	stimulant	_
22-23	3259-3263	user	_
22-24	3264-3265	.	_

Text=This was also used to quantify lifetime years of regular non-stimulant drug and alcohol use.
23-1	3266-3270	This	_
23-2	3271-3274	was	_
23-3	3275-3279	also	_
23-4	3280-3284	used	_
23-5	3285-3287	to	_
23-6	3288-3296	quantify	_
23-7	3297-3305	lifetime	_
23-8	3306-3311	years	_
23-9	3312-3314	of	_
23-10	3315-3322	regular	_
23-11	3323-3336	non-stimulant	_
23-12	3337-3341	drug	_
23-13	3342-3345	and	_
23-14	3346-3353	alcohol	_
23-15	3354-3357	use	_
23-16	3358-3359	.	_

Text=Although methamphetamine and cocaine are distinct substances, both are stimulant class and there is precedent for examining their use together [i.e.,], as well as evidence that the substances have similar trajectories, effects on the brain and outcomes.
24-1	3360-3368	Although	_
24-2	3369-3384	methamphetamine	_
24-3	3385-3388	and	_
24-4	3389-3396	cocaine	_
24-5	3397-3400	are	_
24-6	3401-3409	distinct	_
24-7	3410-3420	substances	_
24-8	3421-3422	,	_
24-9	3423-3427	both	_
24-10	3428-3431	are	_
24-11	3432-3441	stimulant	_
24-12	3442-3447	class	_
24-13	3448-3451	and	_
24-14	3452-3457	there	_
24-15	3458-3460	is	_
24-16	3461-3470	precedent	_
24-17	3471-3474	for	_
24-18	3475-3484	examining	_
24-19	3485-3490	their	_
24-20	3491-3494	use	_
24-21	3495-3503	together	_
24-22	3504-3505	[	_
24-23	3506-3510	i.e.	_
24-24	3511-3512	,	_
24-25	3513-3514	]	_
24-26	3515-3516	,	_
24-27	3517-3519	as	_
24-28	3520-3524	well	_
24-29	3525-3527	as	_
24-30	3528-3536	evidence	_
24-31	3537-3541	that	_
24-32	3542-3545	the	_
24-33	3546-3556	substances	_
24-34	3557-3561	have	_
24-35	3562-3569	similar	_
24-36	3570-3582	trajectories	_
24-37	3583-3584	,	_
24-38	3585-3592	effects	_
24-39	3593-3595	on	_
24-40	3596-3599	the	_
24-41	3600-3605	brain	_
24-42	3606-3609	and	_
24-43	3610-3618	outcomes	_
24-44	3619-3620	.	_

Text=In addition to the ASI-X, we collected additional measures to quantify possible confounding factors as well as to evaluate for the exclusion criteria discussed above.
25-1	3621-3623	In	_
25-2	3624-3632	addition	_
25-3	3633-3635	to	_
25-4	3636-3639	the	_
25-5	3640-3645	ASI-X	_
25-6	3646-3647	,	_
25-7	3648-3650	we	_
25-8	3651-3660	collected	_
25-9	3661-3671	additional	_
25-10	3672-3680	measures	_
25-11	3681-3683	to	_
25-12	3684-3692	quantify	_
25-13	3693-3701	possible	_
25-14	3702-3713	confounding	_
25-15	3714-3721	factors	_
25-16	3722-3724	as	_
25-17	3725-3729	well	_
25-18	3730-3732	as	_
25-19	3733-3735	to	_
25-20	3736-3744	evaluate	_
25-21	3745-3748	for	_
25-22	3749-3752	the	_
25-23	3753-3762	exclusion	_
25-24	3763-3771	criteria	_
25-25	3772-3781	discussed	_
25-26	3782-3787	above	_
25-27	3788-3789	.	_

Text=Smoking was assessed using the Fagerstrom Test for Nicotine Dependence.
26-1	3790-3797	Smoking	_
26-2	3798-3801	was	_
26-3	3802-3810	assessed	_
26-4	3811-3816	using	_
26-5	3817-3820	the	_
26-6	3821-3831	Fagerstrom	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
26-7	3832-3836	Test	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
26-8	3837-3840	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
26-9	3841-3849	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
26-10	3850-3860	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
26-11	3861-3862	.	_

Text=IQ was estimated using the Vocabulary and Matrix Reasoning subtests of the Adult Intelligence Scale (WAIS).
27-1	3863-3865	IQ	_
27-2	3866-3869	was	_
27-3	3870-3879	estimated	_
27-4	3880-3885	using	_
27-5	3886-3889	the	_
27-6	3890-3900	Vocabulary	_
27-7	3901-3904	and	_
27-8	3905-3911	Matrix	_
27-9	3912-3921	Reasoning	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
27-10	3922-3930	subtests	_
27-11	3931-3933	of	_
27-12	3934-3937	the	_
27-13	3938-3943	Adult	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
27-14	3944-3956	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
27-15	3957-3962	Scale	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
27-16	3963-3964	(	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
27-17	3965-3969	WAIS	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
27-18	3970-3971	)	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
27-19	3972-3973	.	_

Text=Because stimulant use is likely to be comorbid with psychopathy, psychopathy and stimulant abuse show overlapping brain regions of decreased structure/function, and psychopathy is higher among incarcerated versus non-incarcerated individuals, psychopathy was assessed in all study participants using the Hare Psychopathy Checklist- Revised (PCL-R).
28-1	3974-3981	Because	_
28-2	3982-3991	stimulant	_
28-3	3992-3995	use	_
28-4	3996-3998	is	_
28-5	3999-4005	likely	_
28-6	4006-4008	to	_
28-7	4009-4011	be	_
28-8	4012-4020	comorbid	_
28-9	4021-4025	with	_
28-10	4026-4037	psychopathy	_
28-11	4038-4039	,	_
28-12	4040-4051	psychopathy	_
28-13	4052-4055	and	_
28-14	4056-4065	stimulant	_
28-15	4066-4071	abuse	_
28-16	4072-4076	show	_
28-17	4077-4088	overlapping	_
28-18	4089-4094	brain	_
28-19	4095-4102	regions	_
28-20	4103-4105	of	_
28-21	4106-4115	decreased	_
28-22	4116-4134	structure/function	_
28-23	4135-4136	,	_
28-24	4137-4140	and	_
28-25	4141-4152	psychopathy	_
28-26	4153-4155	is	_
28-27	4156-4162	higher	_
28-28	4163-4168	among	_
28-29	4169-4181	incarcerated	_
28-30	4182-4188	versus	_
28-31	4189-4205	non-incarcerated	_
28-32	4206-4217	individuals	_
28-33	4218-4219	,	_
28-34	4220-4231	psychopathy	_
28-35	4232-4235	was	_
28-36	4236-4244	assessed	_
28-37	4245-4247	in	_
28-38	4248-4251	all	_
28-39	4252-4257	study	_
28-40	4258-4270	participants	_
28-41	4271-4276	using	_
28-42	4277-4280	the	_
28-43	4281-4285	Hare	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale
28-44	4286-4297	Psychopathy	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale
28-45	4298-4308	Checklist-	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale
28-46	4309-4316	Revised	_
28-47	4317-4318	(	_
28-48	4319-4324	PCL-R	_
28-49	4325-4326	)	_
28-50	4327-4328	.	_

Text=The PCL-R is the most widely used assessment of psychopathy in forensic populations, consisting of a semi-structured interview on topics such as interpersonal style and criminal history.
29-1	4329-4332	The	_
29-2	4333-4338	PCL-R	_
29-3	4339-4341	is	_
29-4	4342-4345	the	_
29-5	4346-4350	most	_
29-6	4351-4357	widely	_
29-7	4358-4362	used	_
29-8	4363-4373	assessment	_
29-9	4374-4376	of	_
29-10	4377-4388	psychopathy	_
29-11	4389-4391	in	_
29-12	4392-4400	forensic	_
29-13	4401-4412	populations	_
29-14	4413-4414	,	_
29-15	4415-4425	consisting	_
29-16	4426-4428	of	_
29-17	4429-4430	a	_
29-18	4431-4446	semi-structured	_
29-19	4447-4456	interview	_
29-20	4457-4459	on	_
29-21	4460-4466	topics	_
29-22	4467-4471	such	_
29-23	4472-4474	as	_
29-24	4475-4488	interpersonal	_
29-25	4489-4494	style	_
29-26	4495-4498	and	_
29-27	4499-4507	criminal	_
29-28	4508-4515	history	_
29-29	4516-4517	.	_

Text=Participants are scored on a scale of 0–40, where higher scores indicate stronger psychopathic traits.
30-1	4518-4530	Participants	_
30-2	4531-4534	are	_
30-3	4535-4541	scored	_
30-4	4542-4544	on	_
30-5	4545-4546	a	_
30-6	4547-4552	scale	_
30-7	4553-4555	of	_
30-8	4556-4560	0–40	_
30-9	4561-4562	,	_
30-10	4563-4568	where	_
30-11	4569-4575	higher	_
30-12	4576-4582	scores	_
30-13	4583-4591	indicate	_
30-14	4592-4600	stronger	_
30-15	4601-4613	psychopathic	_
30-16	4614-4620	traits	_
30-17	4621-4622	.	_

Text=Psychiatric histories were assessed with the Structured Clinical Interview for DSM-IV disorders (SCID) both to evaluate psychotic disorders for exclusion purposes and to evaluate other Axis I disorders.
31-1	4623-4634	Psychiatric	_
31-2	4635-4644	histories	_
31-3	4645-4649	were	_
31-4	4650-4658	assessed	_
31-5	4659-4663	with	_
31-6	4664-4667	the	_
31-7	4668-4678	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
31-8	4679-4687	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
31-9	4688-4697	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
31-10	4698-4701	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
31-11	4702-4708	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
31-12	4709-4718	disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
31-13	4719-4720	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
31-14	4721-4725	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
31-15	4726-4727	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
31-16	4728-4732	both	_
31-17	4733-4735	to	_
31-18	4736-4744	evaluate	_
31-19	4745-4754	psychotic	_
31-20	4755-4764	disorders	_
31-21	4765-4768	for	_
31-22	4769-4778	exclusion	_
31-23	4779-4787	purposes	_
31-24	4788-4791	and	_
31-25	4792-4794	to	_
31-26	4795-4803	evaluate	_
31-27	4804-4809	other	_
31-28	4810-4814	Axis	_
31-29	4815-4816	I	_
31-30	4817-4826	disorders	_
31-31	4827-4828	.	_

Text=All interviews were conducted by trained research staff.
32-1	4829-4832	All	_
32-2	4833-4843	interviews	_
32-3	4844-4848	were	_
32-4	4849-4858	conducted	_
32-5	4859-4861	by	_
32-6	4862-4869	trained	_
32-7	4870-4878	research	_
32-8	4879-4884	staff	_
32-9	4885-4886	.	_

Text=Moral task Participants were shown words and phrases describing moral acts or concepts adapted from a task previously developed and validated by.
33-1	4887-4892	Moral	_
33-2	4893-4897	task	_
33-3	4898-4910	Participants	_
33-4	4911-4915	were	_
33-5	4916-4921	shown	_
33-6	4922-4927	words	_
33-7	4928-4931	and	_
33-8	4932-4939	phrases	_
33-9	4940-4950	describing	_
33-10	4951-4956	moral	_
33-11	4957-4961	acts	_
33-12	4962-4964	or	_
33-13	4965-4973	concepts	_
33-14	4974-4981	adapted	_
33-15	4982-4986	from	_
33-16	4987-4988	a	_
33-17	4989-4993	task	_
33-18	4994-5004	previously	_
33-19	5005-5014	developed	_
33-20	5015-5018	and	_
33-21	5019-5028	validated	_
33-22	5029-5031	by	_
33-23	5032-5033	.	_

Text=Fifty stimuli were classified as noncontroversial negative (e.g., murder, slavery), fifty were classified as noncontroversial positive (e.g., charity, kindness), and fifty were classified as controversial (e.g., animal testing, gun control).
34-1	5034-5039	Fifty	_
34-2	5040-5047	stimuli	_
34-3	5048-5052	were	_
34-4	5053-5063	classified	_
34-5	5064-5066	as	_
34-6	5067-5083	noncontroversial	_
34-7	5084-5092	negative	_
34-8	5093-5094	(	_
34-9	5095-5099	e.g.	_
34-10	5100-5101	,	_
34-11	5102-5108	murder	_
34-12	5109-5110	,	_
34-13	5111-5118	slavery	_
34-14	5119-5120	)	_
34-15	5121-5122	,	_
34-16	5123-5128	fifty	_
34-17	5129-5133	were	_
34-18	5134-5144	classified	_
34-19	5145-5147	as	_
34-20	5148-5164	noncontroversial	_
34-21	5165-5173	positive	_
34-22	5174-5175	(	_
34-23	5176-5180	e.g.	_
34-24	5181-5182	,	_
34-25	5183-5190	charity	_
34-26	5191-5192	,	_
34-27	5193-5201	kindness	_
34-28	5202-5203	)	_
34-29	5204-5205	,	_
34-30	5206-5209	and	_
34-31	5210-5215	fifty	_
34-32	5216-5220	were	_
34-33	5221-5231	classified	_
34-34	5232-5234	as	_
34-35	5235-5248	controversial	_
34-36	5249-5250	(	_
34-37	5251-5255	e.g.	_
34-38	5256-5257	,	_
34-39	5258-5264	animal	_
34-40	5265-5272	testing	_
34-41	5273-5274	,	_
34-42	5275-5278	gun	_
34-43	5279-5286	control	_
34-44	5287-5288	)	_
34-45	5289-5290	.	_

Text=Controversial stimuli required more processing than noncontroversial stimuli; this was confirmed in our study by an increased response time to the stimuli.
35-1	5291-5304	Controversial	_
35-2	5305-5312	stimuli	_
35-3	5313-5321	required	_
35-4	5322-5326	more	_
35-5	5327-5337	processing	_
35-6	5338-5342	than	_
35-7	5343-5359	noncontroversial	_
35-8	5360-5367	stimuli	_
35-9	5368-5369	;	_
35-10	5370-5374	this	_
35-11	5375-5378	was	_
35-12	5379-5388	confirmed	_
35-13	5389-5391	in	_
35-14	5392-5395	our	_
35-15	5396-5401	study	_
35-16	5402-5404	by	_
35-17	5405-5407	an	_
35-18	5408-5417	increased	_
35-19	5418-5426	response	_
35-20	5427-5431	time	_
35-21	5432-5434	to	_
35-22	5435-5438	the	_
35-23	5439-5446	stimuli	_
35-24	5447-5448	.	_

Text=Participants were presented with a given stimulus and asked to press one button to indicate they thought the word or phrase was morally wrong and a different button to indicate that they thought the stimuli was morally not wrong.
36-1	5449-5461	Participants	_
36-2	5462-5466	were	_
36-3	5467-5476	presented	_
36-4	5477-5481	with	_
36-5	5482-5483	a	_
36-6	5484-5489	given	_
36-7	5490-5498	stimulus	_
36-8	5499-5502	and	_
36-9	5503-5508	asked	_
36-10	5509-5511	to	_
36-11	5512-5517	press	_
36-12	5518-5521	one	_
36-13	5522-5528	button	_
36-14	5529-5531	to	_
36-15	5532-5540	indicate	_
36-16	5541-5545	they	_
36-17	5546-5553	thought	_
36-18	5554-5557	the	_
36-19	5558-5562	word	_
36-20	5563-5565	or	_
36-21	5566-5572	phrase	_
36-22	5573-5576	was	_
36-23	5577-5584	morally	_
36-24	5585-5590	wrong	_
36-25	5591-5594	and	_
36-26	5595-5596	a	_
36-27	5597-5606	different	_
36-28	5607-5613	button	_
36-29	5614-5616	to	_
36-30	5617-5625	indicate	_
36-31	5626-5630	that	_
36-32	5631-5635	they	_
36-33	5636-5643	thought	_
36-34	5644-5647	the	_
36-35	5648-5655	stimuli	_
36-36	5656-5659	was	_
36-37	5660-5667	morally	_
36-38	5668-5671	not	_
36-39	5672-5677	wrong	_
36-40	5678-5679	.	_

Text=After the button was pressed, a black screen was shown jittered for 1 to 6 seconds.
37-1	5680-5685	After	_
37-2	5686-5689	the	_
37-3	5690-5696	button	_
37-4	5697-5700	was	_
37-5	5701-5708	pressed	_
37-6	5709-5710	,	_
37-7	5711-5712	a	_
37-8	5713-5718	black	_
37-9	5719-5725	screen	_
37-10	5726-5729	was	_
37-11	5730-5735	shown	_
37-12	5736-5744	jittered	_
37-13	5745-5748	for	_
37-14	5749-5750	1	_
37-15	5751-5753	to	_
37-16	5754-5755	6	_
37-17	5756-5763	seconds	_
37-18	5764-5765	.	_

Text=Three runs of the task were administered, each including 50 stimuli evenly divided amongst stimulus types.
38-1	5766-5771	Three	_
38-2	5772-5776	runs	_
38-3	5777-5779	of	_
38-4	5780-5783	the	_
38-5	5784-5788	task	_
38-6	5789-5793	were	_
38-7	5794-5806	administered	_
38-8	5807-5808	,	_
38-9	5809-5813	each	_
38-10	5814-5823	including	_
38-11	5824-5826	50	_
38-12	5827-5834	stimuli	_
38-13	5835-5841	evenly	_
38-14	5842-5849	divided	_
38-15	5850-5857	amongst	_
38-16	5858-5866	stimulus	_
38-17	5867-5872	types	_
38-18	5873-5874	.	_

Text=MRI data acquisition Participants were scanned using the Mind Research Network ’ s 1.5T Siemens Avanto mobile MRI scanner stationed at correctional facilities.
39-1	5875-5878	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-2	5879-5883	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-3	5884-5895	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-4	5896-5908	Participants	_
39-5	5909-5913	were	_
39-6	5914-5921	scanned	_
39-7	5922-5927	using	_
39-8	5928-5931	the	_
39-9	5932-5936	Mind	_
39-10	5937-5945	Research	_
39-11	5946-5953	Network	_
39-12	5954-5955	’	_
39-13	5956-5957	s	_
39-14	5958-5962	1.5T	_
39-15	5963-5970	Siemens	_
39-16	5971-5977	Avanto	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-17	5978-5984	mobile	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-18	5985-5988	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-19	5989-5996	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-20	5997-6006	stationed	_
39-21	6007-6009	at	_
39-22	6010-6022	correctional	_
39-23	6023-6033	facilities	_
39-24	6034-6035	.	_

Text=The scans were acquired using an EPI gradient-echo pulse sequence (parameters: repetition time (TR) 2000, echo time (TE) 39 ms, flip angle 75°, FOV 24 x 24 cm, 64 x 64 matrix, 4 mm slice thickness with a 1mm gap, 27 slices).
40-1	6036-6039	The	_
40-2	6040-6045	scans	_
40-3	6046-6050	were	_
40-4	6051-6059	acquired	_
40-5	6060-6065	using	_
40-6	6066-6068	an	_
40-7	6069-6072	EPI	_
40-8	6073-6086	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#PulseOximetry
40-9	6087-6092	pulse	http://maven.renci.org/NeuroBridge/neurobridge#PulseOximetry
40-10	6093-6101	sequence	_
40-11	6102-6103	(	_
40-12	6104-6114	parameters	_
40-13	6115-6116	:	_
40-14	6117-6127	repetition	_
40-15	6128-6132	time	_
40-16	6133-6134	(	_
40-17	6135-6137	TR	_
40-18	6138-6139	)	_
40-19	6140-6144	2000	_
40-20	6145-6146	,	_
40-21	6147-6151	echo	_
40-22	6152-6156	time	_
40-23	6157-6158	(	_
40-24	6159-6161	TE	_
40-25	6162-6163	)	_
40-26	6164-6166	39	_
40-27	6167-6169	ms	_
40-28	6170-6171	,	_
40-29	6172-6176	flip	_
40-30	6177-6182	angle	_
40-31	6183-6186	75°	_
40-32	6187-6188	,	_
40-33	6189-6192	FOV	_
40-34	6193-6195	24	_
40-35	6196-6197	x	_
40-36	6198-6200	24	_
40-37	6201-6203	cm	_
40-38	6204-6205	,	_
40-39	6206-6208	64	_
40-40	6209-6210	x	_
40-41	6211-6213	64	_
40-42	6214-6220	matrix	_
40-43	6221-6222	,	_
40-44	6223-6224	4	_
40-45	6225-6227	mm	_
40-46	6228-6233	slice	_
40-47	6234-6243	thickness	_
40-48	6244-6248	with	_
40-49	6249-6250	a	_
40-50	6251-6254	1mm	_
40-51	6255-6258	gap	_
40-52	6259-6260	,	_
40-53	6261-6263	27	_
40-54	6264-6270	slices	_
40-55	6271-6272	)	_
40-56	6273-6274	.	_

Text=The task was presented using E-Prime software.
41-1	6275-6278	The	_
41-2	6279-6283	task	_
41-3	6284-6287	was	_
41-4	6288-6297	presented	_
41-5	6298-6303	using	_
41-6	6304-6311	E-Prime	_
41-7	6312-6320	software	_
41-8	6321-6322	.	_

Text=A T1-weighted scan was collected (parameters: TR 2530, TE 1.64 ms, 3.50ms, 5.36ms, 7.22ms, inversion time = 1100 ms, flip angle 7°, slice thickness = 1.3mm, 256 x 256 matrix), but it was not used in any of the functional MRI post-processing.
42-1	6323-6324	A	_
42-2	6325-6336	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
42-3	6337-6341	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
42-4	6342-6345	was	_
42-5	6346-6355	collected	_
42-6	6356-6357	(	_
42-7	6358-6368	parameters	_
42-8	6369-6370	:	_
42-9	6371-6373	TR	_
42-10	6374-6378	2530	_
42-11	6379-6380	,	_
42-12	6381-6383	TE	_
42-13	6384-6388	1.64	_
42-14	6389-6391	ms	_
42-15	6392-6393	,	_
42-16	6394-6400	3.50ms	_
42-17	6401-6402	,	_
42-18	6403-6409	5.36ms	_
42-19	6410-6411	,	_
42-20	6412-6418	7.22ms	_
42-21	6419-6420	,	_
42-22	6421-6430	inversion	_
42-23	6431-6435	time	_
42-24	6436-6437	=	_
42-25	6438-6442	1100	_
42-26	6443-6445	ms	_
42-27	6446-6447	,	_
42-28	6448-6452	flip	_
42-29	6453-6458	angle	_
42-30	6459-6461	7°	_
42-31	6462-6463	,	_
42-32	6464-6469	slice	_
42-33	6470-6479	thickness	_
42-34	6480-6481	=	_
42-35	6482-6487	1.3mm	_
42-36	6488-6489	,	_
42-37	6490-6493	256	_
42-38	6494-6495	x	_
42-39	6496-6499	256	_
42-40	6500-6506	matrix	_
42-41	6507-6508	)	_
42-42	6509-6510	,	_
42-43	6511-6514	but	_
42-44	6515-6517	it	_
42-45	6518-6521	was	_
42-46	6522-6525	not	_
42-47	6526-6530	used	_
42-48	6531-6533	in	_
42-49	6534-6537	any	_
42-50	6538-6540	of	_
42-51	6541-6544	the	_
42-52	6545-6555	functional	_
42-53	6556-6559	MRI	_
42-54	6560-6575	post-processing	_
42-55	6576-6577	.	_

Text=Image preprocessing and analyses Imaging data were preprocessed with Statistical Parametric Mapping software (SPM).
43-1	6578-6583	Image	_
43-2	6584-6597	preprocessing	_
43-3	6598-6601	and	_
43-4	6602-6610	analyses	_
43-5	6611-6618	Imaging	_
43-6	6619-6623	data	_
43-7	6624-6628	were	_
43-8	6629-6641	preprocessed	_
43-9	6642-6646	with	_
43-10	6647-6658	Statistical	_
43-11	6659-6669	Parametric	_
43-12	6670-6677	Mapping	_
43-13	6678-6686	software	_
43-14	6687-6688	(	_
43-15	6689-6692	SPM	_
43-16	6693-6694	)	_
43-17	6695-6696	.	_

Text=Head motion was corrected using the ArtRepair Toolbox in SPM to identify and remove severe artifacts, defined as time points with signal change greater than 4% of the global mean signal, then INRIAlign to estimate head motion using an algorithm that is insensitive to eye movements and blood oxygenation level dependent (BOLD) activity.
44-1	6697-6701	Head	_
44-2	6702-6708	motion	_
44-3	6709-6712	was	_
44-4	6713-6722	corrected	_
44-5	6723-6728	using	_
44-6	6729-6732	the	_
44-7	6733-6742	ArtRepair	_
44-8	6743-6750	Toolbox	_
44-9	6751-6753	in	_
44-10	6754-6757	SPM	_
44-11	6758-6760	to	_
44-12	6761-6769	identify	_
44-13	6770-6773	and	_
44-14	6774-6780	remove	_
44-15	6781-6787	severe	_
44-16	6788-6797	artifacts	_
44-17	6798-6799	,	_
44-18	6800-6807	defined	_
44-19	6808-6810	as	_
44-20	6811-6815	time	_
44-21	6816-6822	points	_
44-22	6823-6827	with	_
44-23	6828-6834	signal	_
44-24	6835-6841	change	_
44-25	6842-6849	greater	_
44-26	6850-6854	than	_
44-27	6855-6856	4	_
44-28	6857-6858	%	_
44-29	6859-6861	of	_
44-30	6862-6865	the	_
44-31	6866-6872	global	_
44-32	6873-6877	mean	_
44-33	6878-6884	signal	_
44-34	6885-6886	,	_
44-35	6887-6891	then	_
44-36	6892-6901	INRIAlign	_
44-37	6902-6904	to	_
44-38	6905-6913	estimate	_
44-39	6914-6918	head	_
44-40	6919-6925	motion	_
44-41	6926-6931	using	_
44-42	6932-6934	an	_
44-43	6935-6944	algorithm	_
44-44	6945-6949	that	_
44-45	6950-6952	is	_
44-46	6953-6964	insensitive	_
44-47	6965-6967	to	_
44-48	6968-6971	eye	_
44-49	6972-6981	movements	_
44-50	6982-6985	and	_
44-51	6986-6991	blood	_
44-52	6992-7003	oxygenation	_
44-53	7004-7009	level	_
44-54	7010-7019	dependent	_
44-55	7020-7021	(	_
44-56	7022-7026	BOLD	_
44-57	7027-7028	)	_
44-58	7029-7037	activity	_
44-59	7038-7039	.	_

Text=We then spatially normalized images to the Montreal Neurological Institute (MNI) template and smoothed with an 8 mm full-width at half-maximum Gaussian smoothing kernel.
45-1	7040-7042	We	_
45-2	7043-7047	then	_
45-3	7048-7057	spatially	_
45-4	7058-7068	normalized	_
45-5	7069-7075	images	_
45-6	7076-7078	to	_
45-7	7079-7082	the	_
45-8	7083-7091	Montreal	_
45-9	7092-7104	Neurological	_
45-10	7105-7114	Institute	_
45-11	7115-7116	(	_
45-12	7117-7120	MNI	_
45-13	7121-7122	)	_
45-14	7123-7131	template	_
45-15	7132-7135	and	_
45-16	7136-7144	smoothed	_
45-17	7145-7149	with	_
45-18	7150-7152	an	_
45-19	7153-7154	8	_
45-20	7155-7157	mm	_
45-21	7158-7168	full-width	_
45-22	7169-7171	at	_
45-23	7172-7184	half-maximum	_
45-24	7185-7193	Gaussian	_
45-25	7194-7203	smoothing	_
45-26	7204-7210	kernel	_
45-27	7211-7212	.	_

Text=A high-pass filter removed low-frequency drift below 1/128 Hertz.
46-1	7213-7214	A	_
46-2	7215-7224	high-pass	_
46-3	7225-7231	filter	_
46-4	7232-7239	removed	_
46-5	7240-7253	low-frequency	_
46-6	7254-7259	drift	_
46-7	7260-7265	below	_
46-8	7266-7271	1/128	_
46-9	7272-7277	Hertz	_
46-10	7278-7279	.	_

Text=We modeled two conditions of interest at the single-subject level using the general linear model (GLM).
47-1	7280-7282	We	_
47-2	7283-7290	modeled	_
47-3	7291-7294	two	_
47-4	7295-7305	conditions	_
47-5	7306-7308	of	_
47-6	7309-7317	interest	_
47-7	7318-7320	at	_
47-8	7321-7324	the	_
47-9	7325-7339	single-subject	_
47-10	7340-7345	level	_
47-11	7346-7351	using	_
47-12	7352-7355	the	_
47-13	7356-7363	general	_
47-14	7364-7370	linear	_
47-15	7371-7376	model	_
47-16	7377-7378	(	_
47-17	7379-7382	GLM	_
47-18	7383-7384	)	_
47-19	7385-7386	.	_

Text=These conditions were controversial and noncontroversial (including both positive and negative stimuli).
48-1	7387-7392	These	_
48-2	7393-7403	conditions	_
48-3	7404-7408	were	_
48-4	7409-7422	controversial	_
48-5	7423-7426	and	_
48-6	7427-7443	noncontroversial	_
48-7	7444-7445	(	_
48-8	7446-7455	including	_
48-9	7456-7460	both	_
48-10	7461-7469	positive	_
48-11	7470-7473	and	_
48-12	7474-7482	negative	_
48-13	7483-7490	stimuli	_
48-14	7491-7492	)	_
48-15	7493-7494	.	_

Text=We examined the conditions time-locked to participant response.
49-1	7495-7497	We	_
49-2	7498-7506	examined	_
49-3	7507-7510	the	_
49-4	7511-7521	conditions	_
49-5	7522-7533	time-locked	_
49-6	7534-7536	to	_
49-7	7537-7548	participant	_
49-8	7549-7557	response	_
49-9	7558-7559	.	_

Text=At the group-level, the conditions of interest were compared using a one-sample t-test (controversial> noncontroversial).
50-1	7560-7562	At	_
50-2	7563-7566	the	_
50-3	7567-7578	group-level	_
50-4	7579-7580	,	_
50-5	7581-7584	the	_
50-6	7585-7595	conditions	_
50-7	7596-7598	of	_
50-8	7599-7607	interest	_
50-9	7608-7612	were	_
50-10	7613-7621	compared	_
50-11	7622-7627	using	_
50-12	7628-7629	a	_
50-13	7630-7640	one-sample	_
50-14	7641-7647	t-test	_
50-15	7648-7649	(	_
50-16	7650-7663	controversial	_
50-17	7664-7665	>	_
50-18	7666-7682	noncontroversial	_
50-19	7683-7684	)	_
50-20	7685-7686	.	_

Text=The main effects of this analysis replicated previous use of this task in healthy controls.
51-1	7687-7690	The	_
51-2	7691-7695	main	_
51-3	7696-7703	effects	_
51-4	7704-7706	of	_
51-5	7707-7711	this	_
51-6	7712-7720	analysis	_
51-7	7721-7731	replicated	_
51-8	7732-7740	previous	_
51-9	7741-7744	use	_
51-10	7745-7747	of	_
51-11	7748-7752	this	_
51-12	7753-7757	task	_
51-13	7758-7760	in	_
51-14	7761-7768	healthy	_
51-15	7769-7777	controls	_
51-16	7778-7779	.	_

Text=We then used a two sample t-test to compare BOLD responses for this contrast between the lifetime stimulant use group and non-stimulant use group.
52-1	7780-7782	We	_
52-2	7783-7787	then	_
52-3	7788-7792	used	_
52-4	7793-7794	a	_
52-5	7795-7798	two	_
52-6	7799-7805	sample	_
52-7	7806-7812	t-test	_
52-8	7813-7815	to	_
52-9	7816-7823	compare	_
52-10	7824-7828	BOLD	_
52-11	7829-7838	responses	_
52-12	7839-7842	for	_
52-13	7843-7847	this	_
52-14	7848-7856	contrast	_
52-15	7857-7864	between	_
52-16	7865-7868	the	_
52-17	7869-7877	lifetime	_
52-18	7878-7887	stimulant	_
52-19	7888-7891	use	_
52-20	7892-7897	group	_
52-21	7898-7901	and	_
52-22	7902-7915	non-stimulant	_
52-23	7916-7919	use	_
52-24	7920-7925	group	_
52-25	7926-7927	.	_

Text=Additionally, we examined the impact of stimulant use duration on moral processing by regressing total years of regular stimulant use in a separate statistical analysis using only participants in the lifetime stimulant use group.
53-1	7928-7940	Additionally	_
53-2	7941-7942	,	_
53-3	7943-7945	we	_
53-4	7946-7954	examined	_
53-5	7955-7958	the	_
53-6	7959-7965	impact	_
53-7	7966-7968	of	_
53-8	7969-7978	stimulant	_
53-9	7979-7982	use	_
53-10	7983-7991	duration	_
53-11	7992-7994	on	_
53-12	7995-8000	moral	_
53-13	8001-8011	processing	_
53-14	8012-8014	by	_
53-15	8015-8025	regressing	_
53-16	8026-8031	total	_
53-17	8032-8037	years	_
53-18	8038-8040	of	_
53-19	8041-8048	regular	_
53-20	8049-8058	stimulant	_
53-21	8059-8062	use	_
53-22	8063-8065	in	_
53-23	8066-8067	a	_
53-24	8068-8076	separate	_
53-25	8077-8088	statistical	_
53-26	8089-8097	analysis	_
53-27	8098-8103	using	_
53-28	8104-8108	only	_
53-29	8109-8121	participants	_
53-30	8122-8124	in	_
53-31	8125-8128	the	_
53-32	8129-8137	lifetime	_
53-33	8138-8147	stimulant	_
53-34	8148-8151	use	_
53-35	8152-8157	group	_
53-36	8158-8159	.	_

Text=This stimulant use duration measure may in part quantify stimulant use severity.
54-1	8160-8164	This	_
54-2	8165-8174	stimulant	_
54-3	8175-8178	use	_
54-4	8179-8187	duration	_
54-5	8188-8195	measure	_
54-6	8196-8199	may	_
54-7	8200-8202	in	_
54-8	8203-8207	part	_
54-9	8208-8216	quantify	_
54-10	8217-8226	stimulant	_
54-11	8227-8230	use	_
54-12	8231-8239	severity	_
54-13	8240-8241	.	_

Text=We did not use years of non-stimulant substance and alcohol use as a covariate in our primary group comparisons because it was significantly different between groups; this means that including it as a covariate would remove variance from the group difference, not the error variance.
55-1	8242-8244	We	_
55-2	8245-8248	did	_
55-3	8249-8252	not	_
55-4	8253-8256	use	_
55-5	8257-8262	years	_
55-6	8263-8265	of	_
55-7	8266-8279	non-stimulant	_
55-8	8280-8289	substance	_
55-9	8290-8293	and	_
55-10	8294-8301	alcohol	_
55-11	8302-8305	use	_
55-12	8306-8308	as	_
55-13	8309-8310	a	_
55-14	8311-8320	covariate	_
55-15	8321-8323	in	_
55-16	8324-8327	our	_
55-17	8328-8335	primary	_
55-18	8336-8341	group	_
55-19	8342-8353	comparisons	_
55-20	8354-8361	because	_
55-21	8362-8364	it	_
55-22	8365-8368	was	_
55-23	8369-8382	significantly	_
55-24	8383-8392	different	_
55-25	8393-8400	between	_
55-26	8401-8407	groups	_
55-27	8408-8409	;	_
55-28	8410-8414	this	_
55-29	8415-8420	means	_
55-30	8421-8425	that	_
55-31	8426-8435	including	_
55-32	8436-8438	it	_
55-33	8439-8441	as	_
55-34	8442-8443	a	_
55-35	8444-8453	covariate	_
55-36	8454-8459	would	_
55-37	8460-8466	remove	_
55-38	8467-8475	variance	_
55-39	8476-8480	from	_
55-40	8481-8484	the	_
55-41	8485-8490	group	_
55-42	8491-8501	difference	_
55-43	8502-8503	,	_
55-44	8504-8507	not	_
55-45	8508-8511	the	_
55-46	8512-8517	error	_
55-47	8518-8526	variance	_
55-48	8527-8528	.	_

Text=In order to control for confounding variables in the regression model only, we used years of non-stimulant substance and alcohol use as a covariate in the regression of hemodynamic response by stimulant use duration; we also added age (significantly related to duration of stimulant use: r = .272, p = .002, two-tailed Pearson, and PCL-R Total score to the model, but did not see substantive differences in the results.
56-1	8529-8531	In	_
56-2	8532-8537	order	_
56-3	8538-8540	to	_
56-4	8541-8548	control	_
56-5	8549-8552	for	_
56-6	8553-8564	confounding	_
56-7	8565-8574	variables	_
56-8	8575-8577	in	_
56-9	8578-8581	the	_
56-10	8582-8592	regression	_
56-11	8593-8598	model	_
56-12	8599-8603	only	_
56-13	8604-8605	,	_
56-14	8606-8608	we	_
56-15	8609-8613	used	_
56-16	8614-8619	years	_
56-17	8620-8622	of	_
56-18	8623-8636	non-stimulant	_
56-19	8637-8646	substance	_
56-20	8647-8650	and	_
56-21	8651-8658	alcohol	_
56-22	8659-8662	use	_
56-23	8663-8665	as	_
56-24	8666-8667	a	_
56-25	8668-8677	covariate	_
56-26	8678-8680	in	_
56-27	8681-8684	the	_
56-28	8685-8695	regression	_
56-29	8696-8698	of	_
56-30	8699-8710	hemodynamic	_
56-31	8711-8719	response	_
56-32	8720-8722	by	_
56-33	8723-8732	stimulant	_
56-34	8733-8736	use	_
56-35	8737-8745	duration	_
56-36	8746-8747	;	_
56-37	8748-8750	we	_
56-38	8751-8755	also	_
56-39	8756-8761	added	_
56-40	8762-8765	age	_
56-41	8766-8767	(	_
56-42	8768-8781	significantly	_
56-43	8782-8789	related	_
56-44	8790-8792	to	_
56-45	8793-8801	duration	_
56-46	8802-8804	of	_
56-47	8805-8814	stimulant	_
56-48	8815-8818	use	_
56-49	8819-8820	:	_
56-50	8821-8822	r	_
56-51	8823-8824	=	_
56-52	8825-8829	.272	_
56-53	8830-8831	,	_
56-54	8832-8833	p	_
56-55	8834-8835	=	_
56-56	8836-8840	.002	_
56-57	8841-8842	,	_
56-58	8843-8853	two-tailed	_
56-59	8854-8861	Pearson	_
56-60	8862-8863	,	_
56-61	8864-8867	and	_
56-62	8868-8873	PCL-R	_
56-63	8874-8879	Total	_
56-64	8880-8885	score	_
56-65	8886-8888	to	_
56-66	8889-8892	the	_
56-67	8893-8898	model	_
56-68	8899-8900	,	_
56-69	8901-8904	but	_
56-70	8905-8908	did	_
56-71	8909-8912	not	_
56-72	8913-8916	see	_
56-73	8917-8928	substantive	_
56-74	8929-8940	differences	_
56-75	8941-8943	in	_
56-76	8944-8947	the	_
56-77	8948-8955	results	_
56-78	8956-8957	.	_

Text=To test our hypotheses, a priori brain regions of interest (ROIs) were examined including the ACC, PCC, amygdala, and vmPFC.
57-1	8958-8960	To	_
57-2	8961-8965	test	_
57-3	8966-8969	our	_
57-4	8970-8980	hypotheses	_
57-5	8981-8982	,	_
57-6	8983-8984	a	_
57-7	8985-8991	priori	_
57-8	8992-8997	brain	_
57-9	8998-9005	regions	_
57-10	9006-9008	of	_
57-11	9009-9017	interest	_
57-12	9018-9019	(	_
57-13	9020-9024	ROIs	_
57-14	9025-9026	)	_
57-15	9027-9031	were	_
57-16	9032-9040	examined	_
57-17	9041-9050	including	_
57-18	9051-9054	the	_
57-19	9055-9058	ACC	_
57-20	9059-9060	,	_
57-21	9061-9064	PCC	_
57-22	9065-9066	,	_
57-23	9067-9075	amygdala	_
57-24	9076-9077	,	_
57-25	9078-9081	and	_
57-26	9082-9087	vmPFC	_
57-27	9088-9089	.	_

Text=Anatomical masks of these regions were generated from Wake Forest University Pick Atlas in SPM.
58-1	9090-9100	Anatomical	_
58-2	9101-9106	masks	_
58-3	9107-9109	of	_
58-4	9110-9115	these	_
58-5	9116-9123	regions	_
58-6	9124-9128	were	_
58-7	9129-9138	generated	_
58-8	9139-9143	from	_
58-9	9144-9148	Wake	_
58-10	9149-9155	Forest	_
58-11	9156-9166	University	_
58-12	9167-9171	Pick	_
58-13	9172-9177	Atlas	_
58-14	9178-9180	in	_
58-15	9181-9184	SPM	_
58-16	9185-9186	.	_

Text=A small-volume correction (SVC) was applied to determine the corrected p-values based on the size of each ROI using family wise error (FWE) rate correction for multiple comparisons.
59-1	9187-9188	A	_
59-2	9189-9201	small-volume	_
59-3	9202-9212	correction	_
59-4	9213-9214	(	_
59-5	9215-9218	SVC	_
59-6	9219-9220	)	_
59-7	9221-9224	was	_
59-8	9225-9232	applied	_
59-9	9233-9235	to	_
59-10	9236-9245	determine	_
59-11	9246-9249	the	_
59-12	9250-9259	corrected	_
59-13	9260-9268	p-values	_
59-14	9269-9274	based	_
59-15	9275-9277	on	_
59-16	9278-9281	the	_
59-17	9282-9286	size	_
59-18	9287-9289	of	_
59-19	9290-9294	each	_
59-20	9295-9298	ROI	_
59-21	9299-9304	using	_
59-22	9305-9311	family	_
59-23	9312-9316	wise	_
59-24	9317-9322	error	_
59-25	9323-9324	(	_
59-26	9325-9328	FWE	_
59-27	9329-9330	)	_
59-28	9331-9335	rate	_
59-29	9336-9346	correction	_
59-30	9347-9350	for	_
59-31	9351-9359	multiple	_
59-32	9360-9371	comparisons	_
59-33	9372-9373	.	_

Text=ROIs are represented in Figure 1.
60-1	9374-9378	ROIs	_
60-2	9379-9382	are	_
60-3	9383-9394	represented	_
60-4	9395-9397	in	_
60-5	9398-9404	Figure	_
60-6	9405-9406	1	_
60-7	9407-9408	.	_

Text=Additionally, a whole brain analysis corrected using FWE at p <.05 was conducted to examine areas outside our a priori regions of interest.
61-1	9409-9421	Additionally	_
61-2	9422-9423	,	_
61-3	9424-9425	a	_
61-4	9426-9431	whole	_
61-5	9432-9437	brain	_
61-6	9438-9446	analysis	_
61-7	9447-9456	corrected	_
61-8	9457-9462	using	_
61-9	9463-9466	FWE	_
61-10	9467-9469	at	_
61-11	9470-9471	p	_
61-12	9472-9473	<	_
61-13	9474-9477	.05	_
61-14	9478-9481	was	_
61-15	9482-9491	conducted	_
61-16	9492-9494	to	_
61-17	9495-9502	examine	_
61-18	9503-9508	areas	_
61-19	9509-9516	outside	_
61-20	9517-9520	our	_
61-21	9521-9522	a	_
61-22	9523-9529	priori	_
61-23	9530-9537	regions	_
61-24	9538-9540	of	_
61-25	9541-9549	interest	_
61-26	9550-9551	.	_

Text=In order to understand the contribution of cocaine and methamphetamine use to the overall stimulant use effects, we ran additional analyses with the same contrast, covariates, and ROIs.
62-1	9552-9554	In	_
62-2	9555-9560	order	_
62-3	9561-9563	to	_
62-4	9564-9574	understand	_
62-5	9575-9578	the	_
62-6	9579-9591	contribution	_
62-7	9592-9594	of	_
62-8	9595-9602	cocaine	_
62-9	9603-9606	and	_
62-10	9607-9622	methamphetamine	_
62-11	9623-9626	use	_
62-12	9627-9629	to	_
62-13	9630-9633	the	_
62-14	9634-9641	overall	_
62-15	9642-9651	stimulant	_
62-16	9652-9655	use	_
62-17	9656-9663	effects	_
62-18	9664-9665	,	_
62-19	9666-9668	we	_
62-20	9669-9672	ran	_
62-21	9673-9683	additional	_
62-22	9684-9692	analyses	_
62-23	9693-9697	with	_
62-24	9698-9701	the	_
62-25	9702-9706	same	_
62-26	9707-9715	contrast	_
62-27	9716-9717	,	_
62-28	9718-9728	covariates	_
62-29	9729-9730	,	_
62-30	9731-9734	and	_
62-31	9735-9739	ROIs	_
62-32	9740-9741	.	_

Text=The analyses were as follows: 1) lifetime cocaine users (n = 118) versus non-cocaine users (n = 93); 2) lifetime methamphetamine users (n = 72) versus non-methamphetamine users (n = 139); 3) duration of lifetime cocaine use (n = 118); and 4) duration of lifetime methamphetamine use (n = 72).
63-1	9742-9745	The	_
63-2	9746-9754	analyses	_
63-3	9755-9759	were	_
63-4	9760-9762	as	_
63-5	9763-9770	follows	_
63-6	9771-9772	:	_
63-7	9773-9774	1	_
63-8	9775-9776	)	_
63-9	9777-9785	lifetime	_
63-10	9786-9793	cocaine	_
63-11	9794-9799	users	_
63-12	9800-9801	(	_
63-13	9802-9803	n	_
63-14	9804-9805	=	_
63-15	9806-9809	118	_
63-16	9810-9811	)	_
63-17	9812-9818	versus	_
63-18	9819-9830	non-cocaine	_
63-19	9831-9836	users	_
63-20	9837-9838	(	_
63-21	9839-9840	n	_
63-22	9841-9842	=	_
63-23	9843-9845	93	_
63-24	9846-9847	)	_
63-25	9848-9849	;	_
63-26	9850-9851	2	_
63-27	9852-9853	)	_
63-28	9854-9862	lifetime	_
63-29	9863-9878	methamphetamine	_
63-30	9879-9884	users	_
63-31	9885-9886	(	_
63-32	9887-9888	n	_
63-33	9889-9890	=	_
63-34	9891-9893	72	_
63-35	9894-9895	)	_
63-36	9896-9902	versus	_
63-37	9903-9922	non-methamphetamine	_
63-38	9923-9928	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
63-39	9929-9930	(	_
63-40	9931-9932	n	_
63-41	9933-9934	=	_
63-42	9935-9938	139	_
63-43	9939-9940	)	_
63-44	9941-9942	;	_
63-45	9943-9944	3	_
63-46	9945-9946	)	_
63-47	9947-9955	duration	_
63-48	9956-9958	of	_
63-49	9959-9967	lifetime	_
63-50	9968-9975	cocaine	_
63-51	9976-9979	use	_
63-52	9980-9981	(	_
63-53	9982-9983	n	_
63-54	9984-9985	=	_
63-55	9986-9989	118	_
63-56	9990-9991	)	_
63-57	9992-9993	;	_
63-58	9994-9997	and	_
63-59	9998-9999	4	_
63-60	10000-10001	)	_
63-61	10002-10010	duration	_
63-62	10011-10013	of	_
63-63	10014-10022	lifetime	_
63-64	10023-10038	methamphetamine	_
63-65	10039-10042	use	_
63-66	10043-10044	(	_
63-67	10045-10046	n	_
63-68	10047-10048	=	_
63-69	10049-10051	72	_
63-70	10052-10053	)	_
63-71	10054-10055	.	_

